MA50534A - Variant d'anticorps et isoforme à activité biologique réduite - Google Patents

Variant d'anticorps et isoforme à activité biologique réduite

Info

Publication number
MA50534A
MA50534A MA050534A MA50534A MA50534A MA 50534 A MA50534 A MA 50534A MA 050534 A MA050534 A MA 050534A MA 50534 A MA50534 A MA 50534A MA 50534 A MA50534 A MA 50534A
Authority
MA
Morocco
Prior art keywords
isoform
biological activity
antibody variant
reduced biological
reduced
Prior art date
Application number
MA050534A
Other languages
English (en)
Inventor
Masakazu Fukuda
Kensaku Hosoguchi
Maki Kuwayama
Satoshi Saitoh
Chifumi Seida
Nobuyuki Tanaka
Yosuke Watanabe
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA50534A publication Critical patent/MA50534A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA050534A 2017-11-01 2018-10-31 Variant d'anticorps et isoforme à activité biologique réduite MA50534A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017212179 2017-11-01

Publications (1)

Publication Number Publication Date
MA50534A true MA50534A (fr) 2020-09-09

Family

ID=66331990

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050534A MA50534A (fr) 2017-11-01 2018-10-31 Variant d'anticorps et isoforme à activité biologique réduite

Country Status (19)

Country Link
US (1) US20200283544A1 (fr)
EP (1) EP3705496A4 (fr)
JP (2) JPWO2019088143A1 (fr)
KR (1) KR20200074209A (fr)
CN (1) CN111479829A (fr)
AR (1) AR113816A1 (fr)
AU (1) AU2018361430A1 (fr)
BR (1) BR112020008393A2 (fr)
CA (1) CA3079053A1 (fr)
CL (1) CL2020001113A1 (fr)
CR (1) CR20200229A (fr)
IL (1) IL274265A (fr)
MA (1) MA50534A (fr)
MX (1) MX2020003472A (fr)
PE (1) PE20210553A1 (fr)
SA (1) SA520411871B1 (fr)
SG (1) SG11202003833TA (fr)
TW (1) TW201930352A (fr)
WO (1) WO2019088143A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
EP3398965A4 (fr) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour favoriser l'efficacité de purification d'un polypeptide contenant une région fc
CN109661241A (zh) 2016-09-06 2019-04-19 中外制药株式会社 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
AU2018361430A1 (en) 2017-11-01 2020-06-11 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
WO2023120561A1 (fr) * 2021-12-22 2023-06-29 中外製薬株式会社 Variant d'anticorps à activité biologique réduite
CN114544839A (zh) * 2022-01-20 2022-05-27 未名生物医药有限公司 一种抗人神经生长因子抗体的电荷变异体检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO2005035754A1 (fr) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite de substitution de proteine fonctionnelle
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP1876236B9 (fr) 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Anticorps de substitution de la fonction du facteur viii de coagulation sanguine
EP4218801A3 (fr) * 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'anticorps pour purifier un anticorps bispécifique
CN101460622A (zh) * 2006-03-31 2009-06-17 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
BRPI0716762A2 (pt) * 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
PL2202245T3 (pl) * 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
MY166429A (en) * 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
EP3147355B1 (fr) * 2010-12-27 2020-07-22 Kyowa Kirin Co., Ltd. Procédé de préparation d'une solution aqueuse contenant un milieu de culture et un agent chélatant
US20140371427A1 (en) 2011-12-07 2014-12-18 Amgen Inc. IgG2 DISULFIDE ISOFORM SEPARATION
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
AU2016245887B2 (en) * 2015-04-10 2021-09-23 Adimab, Llc. Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
EP3395835B1 (fr) * 2015-12-25 2021-02-03 Chugai Seiyaku Kabushiki Kaisha Anticorps présentant une activité accrue et son procédé de modification
AU2018361430A1 (en) 2017-11-01 2020-06-11 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity

Also Published As

Publication number Publication date
CA3079053A1 (fr) 2019-05-09
RU2020117440A3 (fr) 2022-04-01
CR20200229A (es) 2020-07-12
WO2019088143A1 (fr) 2019-05-09
AR113816A1 (es) 2020-06-17
PE20210553A1 (es) 2021-03-17
CN111479829A (zh) 2020-07-31
CL2020001113A1 (es) 2020-11-20
RU2020117440A (ru) 2021-12-01
EP3705496A1 (fr) 2020-09-09
AU2018361430A1 (en) 2020-06-11
TW201930352A (zh) 2019-08-01
IL274265A (en) 2020-06-30
EP3705496A4 (fr) 2021-12-08
SA520411871B1 (ar) 2023-12-19
MX2020003472A (es) 2020-08-03
JP2024037761A (ja) 2024-03-19
BR112020008393A2 (pt) 2020-11-03
KR20200074209A (ko) 2020-06-24
SG11202003833TA (en) 2020-05-28
US20200283544A1 (en) 2020-09-10
JPWO2019088143A1 (ja) 2020-11-12

Similar Documents

Publication Publication Date Title
MA50534A (fr) Variant d'anticorps et isoforme à activité biologique réduite
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA54615A (fr) Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
UA42295S (uk) Комп'ютер
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA51066A (fr) Inhibiteurs d'intégrine
MA45941A (fr) Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation
MA55033A (fr) Formulation d'anticorps thérapeutique
MA52014A (fr) Anticorps anti-klk5 et méthodes d'utilisation
MA53122A (fr) Variants d'anticorps cd38 et leurs utilisations
UA42369S (uk) Комп'ютер
MA55818A (fr) Anticorps et immunoconjugués de fr-alpha biparatopique
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
MA55305A (fr) Anticorps bispécifiques anti-v béta 17/anti-cd123
MA51147A (fr) Associations d'anticorps anti-c5 et utilisations associées
MA43049A (fr) Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
MA56466A (fr) Anticorps anti-epha4
MA55600A (fr) Anticorps anti-ige
MA45167A (fr) Peptidomimétique en épingle à cheveux bêta présentant une activité d'inhibition de l'élastase et formes pharmaceutiques aérosols correspondantes
MA54089A (fr) Anticorps anti-pd-1 humain et procédés d'utilisation associés